ALK (G1269A)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.G1269A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 99.5% | 0.5% | 88.97 |
| 2 | Entrectinib | 98.4% | 1.6% | 93.69 |
| 3 | Repotrectinib | 98.0% | 2.0% | 84.21 |
| 4 | Lorlatinib | 96.6% | 3.4% | 97.24 |
| 5 | Alectinib | 96.3% | 3.7% | 95.49 |
| 6 | Ceritinib | 96.2% | 3.8% | 95.44 |
| 7 | Brigatinib | 95.2% | 4.8% | 82.96 |
| 8 | Crizotinib | 94.8% | 5.2% | 91.39 |
| 9 | Nintedanib | 90.2% | 9.8% | 90.23 |
| 10 | Bosutinib | 90.2% | 9.8% | 87.22 |
| 11 | Osimertinib | 86.8% | 13.2% | 97.24 |
| 12 | Lazertinib | 82.9% | 17.1% | 97.47 |
| 13 | Sunitinib | 82.7% | 17.3% | 91.73 |
| 14 | Pralsetinib | 80.9% | 19.1% | 93.43 |
| 15 | Alpelisib | 80.1% | 19.9% | 97.22 |
| 16 | Cabozantinib | 79.9% | 20.1% | 92.73 |
| 17 | Axitinib | 63.6% | 36.4% | 93.23 |
| 18 | Darovasertib | 63.0% | 37.0% | 96.99 |
| 19 | Pacritinib | 59.9% | 40.1% | 88.64 |
| 20 | Fostamatinib | 57.1% | 42.9% | 96.74 |
| 21 | Defactinib | 54.7% | 45.3% | 92.68 |
| 22 | Ponatinib | 49.3% | 50.7% | 78.23 |
| 23 | Neratinib | 43.9% | 56.1% | 93.18 |
| 24 | Fedratinib | 35.6% | 64.4% | 96.21 |
| 25 | Tenalisib | 35.5% | 64.5% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 99.5% | 99.5% | +0.0% |
| Entrectinib | 98.4% | 98.8% | -0.4% |
| Repotrectinib | 98.0% | 99.4% | -1.4% |
| Lorlatinib | 96.6% | 97.2% | -0.6% |
| Alectinib | 96.3% | 98.6% | -2.3% |
| Ceritinib | 96.2% | 98.3% | -2.1% |
| Brigatinib | 95.2% | 99.2% | -4.1% |
| Crizotinib | 94.8% | 97.7% | -2.9% |
| Nintedanib | 90.2% | 84.9% | +5.3% |
| Bosutinib | 90.2% | 75.1% | +15.1% |
| Osimertinib | 86.8% | 80.5% | +6.3% |
| Lazertinib | 82.9% | 46.3% | +36.6% |
| Sunitinib | 82.7% | 87.7% | -5.0% |
| Pralsetinib | 80.9% | 82.6% | -1.7% |
| Alpelisib | 80.1% | 80.7% | -0.6% |
| Cabozantinib | 79.9% | — | — |
| Axitinib | 63.6% | — | — |
| Darovasertib | 63.0% | — | — |
| Pacritinib | 59.9% | 55.3% | +4.6% |
| Fostamatinib | 57.1% | — | — |
| Defactinib | 54.7% | — | — |
| Ponatinib | 49.3% | — | — |
| Neratinib | 43.9% | — | — |
| Fedratinib | 35.6% | — | — |
| Tenalisib | 35.5% | 45.2% | -9.7% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
| epithelioid_inflammatory_myofibroblastic_sarcoma_soft_tissue | Soft Tissue | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 22.9ms